Analysts Set Liquidia Co. (NASDAQ:LQDA) Target Price at $25.38

Shares of Liquidia Co. (NASDAQ:LQDA) have received an average rating of “Buy” from the nine ratings firms that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $25.38.

Several research firms have recently weighed in on LQDA. Wells Fargo & Company started coverage on Liquidia in a research note on Friday, December 20th. They issued an “overweight” rating and a $20.00 price target for the company. Scotiabank started coverage on Liquidia in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $30.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and set a $29.00 price target on shares of Liquidia in a report on Thursday, November 14th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $19.00 price target on shares of Liquidia in a research note on Thursday, January 9th.

Insiders Place Their Bets

In other news, insider Rajeev Saggar sold 2,445 shares of the stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $13.00, for a total value of $31,785.00. Following the completion of the sale, the insider now directly owns 267,943 shares of the company’s stock, valued at $3,483,259. This represents a 0.90 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Roger Jeffs sold 22,343 shares of Liquidia stock in a transaction on Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total transaction of $263,200.54. Following the transaction, the chief executive officer now owns 1,019,177 shares in the company, valued at approximately $12,005,905.06. This trade represents a 2.15 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 73,945 shares of company stock worth $874,403. Company insiders own 30.10% of the company’s stock.

Institutional Trading of Liquidia

Several institutional investors and hedge funds have recently added to or reduced their stakes in LQDA. Steward Partners Investment Advisory LLC purchased a new stake in Liquidia during the 4th quarter valued at approximately $59,000. Signaturefd LLC grew its stake in Liquidia by 38,400.0% during the third quarter. Signaturefd LLC now owns 10,010 shares of the company’s stock valued at $100,000 after acquiring an additional 9,984 shares in the last quarter. Clear Harbor Asset Management LLC bought a new stake in Liquidia in the 3rd quarter valued at $100,000. Ballentine Partners LLC purchased a new stake in Liquidia in the 3rd quarter worth $110,000. Finally, Walleye Trading LLC lifted its stake in Liquidia by 54.7% in the 3rd quarter. Walleye Trading LLC now owns 13,201 shares of the company’s stock worth $132,000 after purchasing an additional 4,670 shares in the last quarter. Institutional investors own 64.54% of the company’s stock.

Liquidia Stock Up 0.2 %

Shares of NASDAQ LQDA opened at $16.26 on Wednesday. The firm has a market cap of $1.38 billion, a P/E ratio of -9.98 and a beta of 0.27. Liquidia has a twelve month low of $8.26 and a twelve month high of $16.99. The company has a 50 day moving average of $12.55 and a 200 day moving average of $11.32.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).